SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Immunology and inflammation
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease
While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set by Amgen’s B cell depleter Uplizna, approved by the FDA for IgG4-related disease last April.
January 6, 2026
 · 
2 min read
 · 
Tristan Manalac
Pleasanton, CA, USA - Feb 21, 2024: Exterior view of the headquarters of Roche Molecular Diagnostics (RMD) in Pleasanton, California. F. Hoffmann-La Roche AG is a Swiss pharmaceutical company.
Obesity
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement
The agreement, which BMO Capital Markets called a “mild positive” for Structure, appears to address Roche’s concerns about the composition of investigational weight loss drug CT-996.
January 6, 2026
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Cancer
Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact
OncoNano’s platform, called ON-BOARD, packages drugs in pH-sensitive micelles that ensure their specific delivery near tumors, while also preventing systemic exposure.
January 6, 2026
 · 
1 min read
 · 
Tristan Manalac
Science abstract background with Stem Cells, molecular structure and GENE. Scientific banner for medicine, biology, chemistry or physics template.
Opinion
Automated Manufacturing Will Meet CAR T Demand
Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, global consistency and broader patient access to CAR T therapies.
January 6, 2026
 · 
3 min read
 · 
Ossama Eissa
Drips faucet and dry environment in the background
IPO
IPOs Slow to a Trickle in 2025 as Investors Grow More Discerning
After a strong open to the year, the public markets suffered a six-month drought that led to biotech’s tightest IPO window in years.
January 6, 2026
 · 
10 min read
 · 
Tristan Manalac
Businessman dares to face problems and chaos
Drug pricing
Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026
Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.
January 6, 2026
 · 
5 min read
 · 
Annalee Armstrong
A look into the future. Concept. stock photo
Manufacturing
2026: Putting the Reindustrialization Mandate Into Practice
Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the new year.
January 6, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Business concept, disagreement, dispute, collapse. The gap between two people. Obstacle to the merger.
FDA
FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025
In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer meetings than usual and agreed with its advisors only 57% of the time, Jefferies reported.
January 6, 2026
 · 
3 min read
 · 
Heather McKenzie
New Year 2026 Numbers made with Glowing Sparklers on Dark Background.
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.
January 5, 2026
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS